The stock of Genetron Holdings Limited (NASDAQ:GTH) last traded at $1.18, up 8.26% from the previous session.
Data from the available sources indicates that Genetron Holdings Limited (NASDAQ:GTH) is covered by 1 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $9.79 and a low of $9.79, we find $9.79. Given the previous closing price of $1.09, this indicates a potential upside of 798.17 percent. GTH stock price is now 19.94% away from the 50-day moving average and -6.43% away from the 200-day moving average. The market capitalization of the company currently stands at $99.20M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
In total, 0 analysts have assigned it a hold rating, and 1 have given it a buy rating. Brokers who have rated the stock have averaged $9.79 as their price target over the next twelve months.
With the price target of $19, Canaccord Genuity recently initiated with Buy rating for Genetron Holdings Limited (NASDAQ: GTH). On July 14, 2020, BTIG Research recently initiated its ‘Buy’ rating on the stock quoting a target price of $20.
A total of 3.85% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GTH stock. A new stake in Genetron Holdings Limited shares was purchased by HUDSON BAY CAPITAL MANAGEMENT LP during the first quarter worth $1,102,000. MAVEN SECURITIES LTD invested $204,000 in shares of GTH during the first quarter. In the first quarter, MILLENNIUM MANAGEMENT LLC acquired a new stake in Genetron Holdings Limited valued at approximately $50,000. ERGOTELES LLC acquired a new stake in GTH for approximately $15,000. In total, there are 42 active investors with 14.30% ownership of the company’s stock.
With an opening price of $1.0700 on Friday morning, Genetron Holdings Limited (NASDAQ: GTH) set off the trading day. During the past 12 months, Genetron Holdings Limited has had a low of $0.73 and a high of $5.10. As of last week, the company has a debt-to-equity ratio of 0.18, a current ratio of 2.80, and a quick ratio of 2.70. The fifty day moving average price for GTH is $0.9908 and a two-hundred day moving average price translates $1.2534 for the stock.
The latest earnings results from Genetron Holdings Limited (NASDAQ: GTH) was released for Jun, 2022. According to the Diagnostics & Research Company, earnings per share came in at -$0.34, missing analysts’ expectations of -$0.03 by -0.31. This compares to -$0.16 EPS in the same period last year. The company reported revenue of $20.57 million for the quarter, compared to $21.76 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -5.48 percent. For the current quarter, analysts expect GTH to generate $22.3M in revenue.
Genetron Holdings Limited(GTH) Company Profile
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People’s Republic of China.
